Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Avelos Therapeutics Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06911333CT.gov AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ad1208 (this asset) | Avelos Therapeutics Inc. | P1/2 | CCC · 48 |
| Catequentinib | Nanfang Hospital, Southern Medical University | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P2 | BB |
| Durvalumab | OHSU Knight Cancer Institute | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Nivolumab | CatalYm GmbH | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Sugemalimab | Second Affiliated Hospital of Soochow University | P2 | BB |
| Atezolizumab | Bionoxx Inc. | P2 | B |
+42 more in the Refractory Malignant Neoplasm cohort
Other indications for ad1208
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ad1208 in Refractory Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ad1208-refractory-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →